We spent 4 exciting days networking with the big players in the industry in California.
"We are overwhelmed by the positive response to our solution for the early diagnosis of Alzheimer's and other diseases," summarizes Christiane Lindig, co-founder and head of corporate development at AIRAmed. Alzheimer's, one of the most feared diseases in our society, already has a much stronger lobby in the US than in Europe.
We were especially pleased to finally meet Paula Rutledge, member of the board of directors of the Alzheimer's Association. We are very grateful for her enthusiasm for AIRAscore. She has tirelessly shared her broad network with us - and now, we are back home with many valuable contacts, new insights, ideas for collaborations in the near future and a lot of energy.
And once again, the enormous potential that a solution like AIRAscore for early diagnosis and therapy monitoring will bring to doctors, patients, relatives, health insurance companies and entire healthcare systems worldwide in the future has been demonstrated.
Also one thing has become clear: Every promising therapy of any kind must be preceded by a meaningful differential diagnosis. And the sooner this can be done, the better!